CN107033093B - N-取代磺酰胺类化合物及其制备方法与应用 - Google Patents
N-取代磺酰胺类化合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN107033093B CN107033093B CN201710423835.1A CN201710423835A CN107033093B CN 107033093 B CN107033093 B CN 107033093B CN 201710423835 A CN201710423835 A CN 201710423835A CN 107033093 B CN107033093 B CN 107033093B
- Authority
- CN
- China
- Prior art keywords
- formula
- phenyl
- dimethyl
- solvent
- substituted sulphonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 N- substituted sulphonamide compound Chemical class 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims abstract description 9
- 229940124530 sulfonamide Drugs 0.000 claims abstract description 9
- 241000588724 Escherichia coli Species 0.000 claims abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 7
- 150000003456 sulfonamides Chemical class 0.000 claims abstract description 6
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims abstract description 5
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 3
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 7
- XBKFUNILASZNBC-UHFFFAOYSA-N 2,4-dimethyl-6-phenyl-1,3,5-triazine Chemical class CC1=NC(C)=NC(C=2C=CC=CC=2)=N1 XBKFUNILASZNBC-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 239000012044 organic layer Substances 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- NHOWDZOIZKMVAI-UHFFFAOYSA-N (2-chlorophenyl)(4-chlorophenyl)pyrimidin-5-ylmethanol Chemical group C=1N=CN=CC=1C(C=1C(=CC=CC=1)Cl)(O)C1=CC=C(Cl)C=C1 NHOWDZOIZKMVAI-UHFFFAOYSA-N 0.000 claims description 2
- RXELBMYKBFKHSM-UHFFFAOYSA-N 2-phenyl-1,3,5-triazine Chemical class C1=CC=CC=C1C1=NC=NC=N1 RXELBMYKBFKHSM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 125000006303 iodophenyl group Chemical group 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 238000012805 post-processing Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001879 copper Chemical class 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- PHRJJOSPUYLRST-UHFFFAOYSA-N 2-n,2-n-dimethyl-6-phenyl-1,3,5-triazine-2,4-diamine Chemical compound CN(C)C1=NC(N)=NC(C=2C=CC=CC=2)=N1 PHRJJOSPUYLRST-UHFFFAOYSA-N 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 239000010949 copper Substances 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 description 1
- JKHHRSIUFVAEOY-UHFFFAOYSA-N 2-iodobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1I JKHHRSIUFVAEOY-UHFFFAOYSA-N 0.000 description 1
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 1
- HHHDJHHNEURCNV-UHFFFAOYSA-N 4-chlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C=C1 HHHDJHHNEURCNV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种如式(II)所示的N‑取代磺酰胺类化合物及其制备方法和应用。制备方法为:将2‑氨基‑4‑二甲胺基‑6‑苯基‑1,3,5‑三嗪与式(I)所示的磺酰胺混合加入溶剂中,在铜盐作用下,在60~150℃温度下搅拌反应5~20小时,反应结束后,反应液后处理制得式(II)所示的N‑取代磺酰胺类化合物。本发明所述的N‑取代磺酰胺类化合物对大肠杆菌有一定的抑制作用,在抗菌药物及抗菌剂的制备中具有应用前景。
Description
技术领域
本发明涉及一类新的N-取代磺酰胺类化合物及其制备方法与应用。
背景技术
磺胺类药物是一类重要的化学合成治疗药,它有着广泛的药理活性,其可通过破坏微管蛋白生成、抑制细胞G1周期、抑制血管生成、抑制碳酸酐酶等作用机制发挥抗肿瘤活性;因此,制备新颖的N-取代磺酰胺类化合物具有重要的理论意义和实际应用价值。
发明内容
本发明采用如下技术方案:
一种如式(II)所示的N-取代磺酰胺类化合物:
式(II)中R为C1~C10烷基、C4~C8杂芳基、C6~C10芳基或C6~C10取代芳基。
进一步,本发明所述R为噻吩基、苯基、邻甲苯基、对氯苯基、对溴苯基或对碘苯基。
本发明还提供一种如式(II)所示的N-取代磺酰胺类化合物的制备方法,其特征在于所述方法为:
将式(Ⅲ)所示的N2,N2-二甲基-6-苯基-1,3,5-三嗪-2,4-二胺与式(I)所示的磺酰胺混合加入溶剂中,在铜盐作用下,在60~150℃温度下搅拌反应5~20小时,反应结束后,反应液后处理制得式(II)所示的N-取代磺酰胺类化合物;所述N2,N2-二甲基-6-苯基-1,3,5-三嗪-2,4-二胺与式(I)所示磺酰胺物质的量比为1:1.0~3.0;所述溶剂为C6~C10芳烃类、C2~C6亚砜类或C3~C6酰胺类溶剂;
式(I)中,R与式(II)中R相同。
进一步,本发明所述N2,N2-二甲基-6-苯基-1,3,5-三嗪-2,4-二胺与铜盐物质的量比为1:0.1~2.0。
进一步,本发明所述铜盐优选为醋酸铜。
进一步,本发明所述溶剂优选为甲苯、氯苯、二甲基亚砜或N,N-二甲基甲酰胺。
通常,本发明所述溶剂的体积用量以N2,N2-二甲基-6-苯基-1,3,5-三嗪-2,4-二胺的质量计为30~60mL/g。
进一步,本发明所述后处理为:反应结束后,加水,用二氯甲烷萃取,合并有机层,浓缩,柱层析分离,以体积比3:1的石油醚和丙酮混合液为洗脱剂,收集含目标化合物的洗脱液,减压蒸除溶剂并干燥,得到目标产物。
此外,本发明提供一种如式(II)所示的芳基取代磺酰胺类化合物在制备抗菌药物或抗菌剂中的应用。
更进一步,本发明所述的抗菌药物为抑制大肠杆菌活性的药物。
本发明开发了结构新颖的N-取代磺酰胺类化合物及其制备方法,该工艺反应条件温和,操作方便,成本低,有着广泛的工业应用前景。本发明所提供的N-取代磺酰胺类化合物显示一定的抗菌活性,为新药筛选及开发奠定了基础,具有较好的实用价值。
具体实施方式
下面结合具体实施例对本发明进行进一步描述,但本发明的保护范围并不仅限于此。
实施例1:
将N2,N2-二甲基-6-苯基-1,3,5-三嗪-2,4-二胺(0.1051g,0.4883mmol)、苯磺酰胺(0.1594g,1.0141mmol)、Cu(OAc)2·H2O(0.0201g,0.1007mmol)在氯苯(3mL)中混合,在90℃条件下反应,TLC跟踪监测,反应20h,反应结束后,加水50mL,用二氯甲烷萃取(20mL×4),合并有机层,浓缩,柱层析(洗脱剂为石油醚:丙酮=3:1,v:v),收集Rf值0.3~0.35的洗脱液(TLC监测,展开剂同洗脱剂),减压蒸馏除去溶剂,干燥得目标化合物(II-1)0.1250g,收率67%。
1H NMR(500MHz,CDCl3):δ13.47(s,1H),8.41(dd,J=8.0,1.6Hz,1H),7.79(dd,J=8.6,1.4Hz,2H),7.64(dd,J=8.3,0.9Hz,1H),7.49–7.44(m,1H),7.40–7.33(m,3H),7.06(td,J=7.4,1.2Hz,1H),5.20(s,2H),3.31(s,3H),3.21(s,3H).
实施例2:
将氯苯改为二甲基甲酰胺(6mL),反应时间改为5h,其他操作同实施例1,得量0.0392g,收率21%。
实施例3:
将氯苯改为甲苯,温度改为60℃,苯磺酰胺的量改为(0.04355g,0.507mmol),其他操作同实施例1,得量0.028g,收率15%。
实施例4:
将氯苯改为二甲基亚砜,温度改为150℃,Cu(OAc)2·H2O的量改为(0.2g,1.002mmol),其他操作同实施例10,得量0.0243g,收率13%。
实施例5:
将Cu(OAc)2·H2O的量改为(0.0100g,0.0501mmol),苯磺酰胺的量改为(0.1306g,1.521mmol)其他操作同实施例1,得量0.097g,收率52%。
实施例6:
将苯磺酰胺改为邻甲苯磺酰胺(0.1735g,1.0133mmol),其他操作同实施例1,制得目标化合物(II-2)0.1360g,收率72%。
1H NMR(500MHz,CDCl3):δ13.68(s,1H),8.48(dd,J=8.0,1.4Hz,1H),8.11(d,J=8.0Hz,1H),7.44–7.37(m,2H),7.31–7.26(m,2H),7.21(d,J=7.5Hz,1H),7.01(td,J=7.5,0.8Hz,1H),5.20(s,2H),3.31(s,3H),3.20(s,3H),2.61(s,3H).
实施例7:
将苯磺酰胺改为对氯苯磺酰胺(0.1924g,1.0040mmol),其他操作同实施例1,制得目标化合物(II-3)0.1296g,收率67%。
1H NMR(500MHz,CDCl3):δ13.41(s,1H),8.40(dd,J=8.0,1.5Hz,1H),7.69(d,J=8.6Hz,2H),7.62(d,J=8.0Hz,1H),7.38(td,J=8.0,1.5Hz,1H),7.33(d,J=8.6Hz,2H),7.10(td,J=8.0,0.7Hz,1H),5.18(s,2H),3.30(s,3H),3.21(s,3H).
实施例8:
将苯磺酰胺改为对溴苯磺酰胺((0.2380g,1.0081mmol),其他操作同实施例1,制得目标化合物(II-4)0.1403g,收率63%。
1H NMR(500MHz,CDCl3):δ13.41(s,1H),8.40(dd,J=8.0,1.6Hz,1H),7.63-7.60(m,3H),7.50(d,J=8.6Hz,2H),7.38(td,J=8.0,1.6Hz,1H),7.10(td,J=8.0,1.0Hz,1H),5.16(s,2H),3.30(s,3H),3.21(s,3H).
实施例9:
将苯磺酰胺改为对碘苯磺酰胺(0.2890g,1.0209mmol),其他操作同实施例1,制得目标化合物(II-5)0.1622g,收率66%。
1H NMR(500MHz,DMSO-d6):δ13.53(s,1H),8.32(dd,J=8.0,1.5Hz,1H),7.85(d,J=8.6Hz,2H),7.51–7.47(m,2H),7.46(d,J=8.6Hz,2H),7.20(s,2H),7.15(td,J=8.0,1.2Hz,1H),3.20(s,3H),3.15(s,3H).
实施例10:
将苯磺酰胺改为2-噻吩磺酰胺(0.3302g,2.0230mmol),其他操作同实施例1,制得目标化合物(II-6)0.1511g,收率41%。
1H NMR(500MHz,DMSO-d6):δ13.78(s,1H),8.37(dd,J=8.0,1.5Hz,1H),7.86(dd,J=4.9,1.3Hz,1H),7.64(dd,J=8.2,1.6Hz,1H),7.54(dd,J=3.8,1.3Hz,1H),7.50(td,J=8.0,1.6Hz,1H),7.19-7.15(m,3H),7.05(dd,J=4.9,3.8Hz,1H),3.20(s,3H),3.14(s,3H)
实施例11:对大肠杆菌(E.coli,Ec)的体外抑菌活性测试
采用扩散法(打孔法)研究了目标化合物在浓度为10mg/mL时对大肠杆菌(E.coli,Ec)的体外抑菌作用。
方法:用灭过菌的打孔器在涂布菌液的平皿上十字对称打6个孔,用无菌微量注射器分别加入100μL质量浓度为10mg/mL的样品二甲基亚砜溶液,并以氨苄青霉素为对照品。将培养皿置于恒温(28℃)培养箱中培养24h,取出观察有无抑菌作用,结果见表2。
表2化合物浓度为10mg/mL体外抗菌活性
Claims (9)
1.一种如式(II)所示的N-取代磺酰胺类化合物:
式(II)中R为噻吩基、苯基、邻甲苯基、对氯苯基、对溴苯基或对碘苯基。
2.一种如权利要求1所述的N-取代磺酰胺类化合物的制备方法,其特征在于所述方法为:
将式(Ⅲ)所示的N2,N2-二甲基-6-苯基-1,3,5-三嗪-2,4-二胺与式(I)所示的磺酰胺混合加入溶剂中,在铜盐的催化作用下,在60~150℃温度下搅拌反应5~20小时,反应结束后,反应液后处理制得式(II)所示的N-取代磺酰胺类化合物;所述N2,N2-二甲基-6-苯基-1,3,5-三嗪-2,4-二胺与式(I)所示磺酰胺物质的量比为1:1.0~3.0;所述溶剂为C6~C10芳烃类、C2~C6亚砜类或C3~C6酰胺类溶剂;
式(I)中,R与式(II)中R相同。
3.如权利要求2所述的方法,其特征在于:所述N2,N2-二甲基-6-苯基-1,3,5-三嗪-2,4-二胺与铜盐物质的量比为1:0.1~2.0。
4.如权利要求2所述的方法,其特征在于:所述铜盐为醋酸铜。
5.如权利要求2所述的方法,其特征在于:所述溶剂为甲苯、氯苯、二甲基亚砜或N,N-二甲基甲酰胺。
6.如权利要求2所述的方法,其特征在于:所述溶剂的体积用量以N2,N2-二甲基-6-苯基-1,3,5-三嗪-2,4-二胺的质量计为30~60mL/g。
7.如权利要求2所述的方法,其特征在于所述后处理为:反应结束后,加水,用二氯甲烷萃取,合并有机层,浓缩,柱层析分离,以体积比3:1的石油醚和丙酮混合液为洗脱剂,收集含目标化合物的洗脱液,减压蒸除溶剂并干燥,得到目标产物。
8.如权利要求1所述的芳基取代磺酰胺类化合物在制备抗菌药物或抗菌剂中的应用。
9.如权利要求8所述的应用,其特征在于:所述的抗菌药物为抑制大肠杆菌活性的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710423835.1A CN107033093B (zh) | 2017-06-07 | 2017-06-07 | N-取代磺酰胺类化合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710423835.1A CN107033093B (zh) | 2017-06-07 | 2017-06-07 | N-取代磺酰胺类化合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107033093A CN107033093A (zh) | 2017-08-11 |
CN107033093B true CN107033093B (zh) | 2019-09-03 |
Family
ID=59542015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710423835.1A Active CN107033093B (zh) | 2017-06-07 | 2017-06-07 | N-取代磺酰胺类化合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107033093B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1726199A (zh) * | 2002-12-17 | 2006-01-25 | 浜理药品工业株式会社 | 新的2,4-二氨基-1,3,5-三嗪衍生物 |
CN1926119A (zh) * | 2004-01-21 | 2007-03-07 | 阿斯利康(瑞典)有限公司 | 作为趋化因子受体调节剂的磺酰胺取代的三嗪化合物 |
CN105732528A (zh) * | 2016-03-25 | 2016-07-06 | 浙江工业大学 | 2-芳胺-4-二甲胺-1,3,5-三嗪类化合物的制备方法 |
CN105753801A (zh) * | 2016-03-25 | 2016-07-13 | 浙江工业大学 | 一种均三嗪类化合物的制备方法 |
CN105820133A (zh) * | 2016-03-25 | 2016-08-03 | 浙江工业大学 | 多取代均三嗪类化合物及其制备方法和应用 |
CN105837525A (zh) * | 2016-03-25 | 2016-08-10 | 浙江工业大学 | 2,4-二胺-1,3,5-三嗪类化合物及其制备方法与应用 |
WO2016129983A1 (en) * | 2015-02-13 | 2016-08-18 | Latvian Institute Of Organic Synthesis | Novel n-acyl-arylsulfonamide derivatives as aminoacyl-trna synthetase inhibitors |
-
2017
- 2017-06-07 CN CN201710423835.1A patent/CN107033093B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1726199A (zh) * | 2002-12-17 | 2006-01-25 | 浜理药品工业株式会社 | 新的2,4-二氨基-1,3,5-三嗪衍生物 |
CN1926119A (zh) * | 2004-01-21 | 2007-03-07 | 阿斯利康(瑞典)有限公司 | 作为趋化因子受体调节剂的磺酰胺取代的三嗪化合物 |
WO2016129983A1 (en) * | 2015-02-13 | 2016-08-18 | Latvian Institute Of Organic Synthesis | Novel n-acyl-arylsulfonamide derivatives as aminoacyl-trna synthetase inhibitors |
CN105732528A (zh) * | 2016-03-25 | 2016-07-06 | 浙江工业大学 | 2-芳胺-4-二甲胺-1,3,5-三嗪类化合物的制备方法 |
CN105753801A (zh) * | 2016-03-25 | 2016-07-13 | 浙江工业大学 | 一种均三嗪类化合物的制备方法 |
CN105820133A (zh) * | 2016-03-25 | 2016-08-03 | 浙江工业大学 | 多取代均三嗪类化合物及其制备方法和应用 |
CN105837525A (zh) * | 2016-03-25 | 2016-08-10 | 浙江工业大学 | 2,4-二胺-1,3,5-三嗪类化合物及其制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
Cu(II)-Mediated C−H Amidation and Amination of Arenes: Exceptional Compatibility with Heterocycles;Ming Shang,等;《J.Am.Chem.Soc.》;20140217;第136卷(第9期);第3354-3357页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107033093A (zh) | 2017-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105837525B (zh) | 2,4-二胺-1,3,5-三嗪类化合物及其制备方法与应用 | |
CN105399695B (zh) | 三嗪类化合物及其制备方法和用途 | |
CN107129499B (zh) | 含咪唑环的稠杂环类化合物及其制备方法和应用 | |
CN107089983B (zh) | 咪唑并均三嗪类化合物及其制备方法和应用 | |
CN107954906B (zh) | 一种芳基磺酰叔胺类化合物的合成方法 | |
CN109651202A (zh) | 利用二甲亚砜叶立德、胺和二氧化碳合成氨基甲酸酯的方法 | |
CN107129498B (zh) | 咪唑芳酮类化合物及其制备方法与应用 | |
CN107033093B (zh) | N-取代磺酰胺类化合物及其制备方法与应用 | |
CN106188044A (zh) | 一种碘催化的3‑芳硫基咪唑并[1,5‑a]N‑杂环化合物的合成方法 | |
CN102060780B (zh) | 2-(n-取代)-氨基苯并咪唑衍生物的制备方法 | |
CN105732648B (zh) | 一种吡咯并呋喃的含氮杂环化合物及合成方法 | |
CN104557663A (zh) | 一种二羰基取代吲哚类医药中间体化合物的合成方法 | |
CN104771392A (zh) | 一类组蛋白去乙酰化酶抑制剂及应用 | |
CN109897033A (zh) | 一种合成含碘咪唑并[1,2a]吡啶类化合物的方法 | |
CN108689892A (zh) | 3-磺酰化-二氢茚酮类化合物及其制备方法 | |
CN107311949B (zh) | 磺酰胺取代的芳基三嗪类化合物及其制备方法与应用 | |
CN105367481B (zh) | 一种3,3-二氟-2-氧化吲哚衍生物的合成方法 | |
CN110194723A (zh) | 一种n-苯甲酰基苯异丝氨酸衍生物及其合成方法和应用 | |
CN104557759A (zh) | 一种制备5-磺酰甲基噁唑衍生物的方法 | |
CN102993105A (zh) | 1-甲基-2,4-喹唑啉二酮衍生物及其制备方法和应用 | |
CN108033913A (zh) | 一种二氢吡唑啉衍生物及其制备方法和应用 | |
CN103724360B (zh) | 吡啶(或苯)并噻唑化合物及其中间体、制备方法和应用 | |
CN107286109B (zh) | 芳基取代磺酰胺类化合物及其制备方法与应用 | |
CN106588749A (zh) | 多取代咔唑类化合物及其合成方法和应用 | |
CN106883172A (zh) | 一种苯丙氨酸类衍生物及其合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240314 Address after: 314000 building 3, Jiake Life Science Park, 3556 linggongtang Road, Daqiao Town, Nanhu District, Jiaxing City, Zhejiang Province Patentee after: Zhejiang Arthur Pharmaceutical Co.,Ltd. Country or region after: China Address before: 310014 No. 18 Chao Wang Road, Xiacheng District, Zhejiang, Hangzhou Patentee before: JIANG University OF TECHNOLOGY Country or region before: China |